CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 122 enrolled
Drug / intervention
Sertraline/omega-3 +1 moredrug
Likely dose
Sertraline 50 mg once daily plus omega-3 2 grams dailyAI-extracted
Key inclusion· 3
  • Current major depressive episode meeting DSM-IV criteria
  • Depression severity: Beck Depression Inventory II score ≥15
  • History of acute myocardial infarction, unstable angina, or documented coronary disease
Key exclusion· 10
  • Active psychosis, dementia, or bipolar disorder
  • Current alcohol or drug abuse
  • Already taking omega-3 supplements
  • Severe hypertriglyceridemia (>400 mg/dL)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00116857
NCT00116857Phase 3Completed

Omega-3 for Depression and Other Cardiac Risk Factors

Washington University School of Medicine·interventional·Posted Jul 1, 2005·Updated Sep 12, 2012

In Brief

A Phase 3 clinical trial evaluating Sertraline/omega-3 and Sertraline/Corn Oil for Cardiovascular Diseases and 4 related conditions. Completed, enrolled 122 participants across 1 site.

Detailed Summary

This study will determine the effects of omega-3 fatty acid (FA) augmentation of sertraline on depression and cardiac endpoints after myocardial infarction (MI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 1, 2005
Enrollment StartFeb 1, 2005
Primary CompletionJun 1, 2009
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 21.0 years ago

Interventions

Sertraline/omega-3drug

Sertraline (50 mgs) plus omega-3 (2 grams)

Sertraline/Corn Oildrug

Sertraline (50 mgs) plus corn oil (2 grams) (placebo)